Biotech News

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Repare Therapeutics (RPTX)Repare Therapeutics2025-08-08 11:00 ESTEarnings

Entered into worldwide licensing agreement with Debiopharm for lunresertib Evaluating strategic alternatives to maximize shareholder value Initial data for LIONS and POLAR trials expected to be reported in Q4 2025 $109.5 million in cash and cash equivalents and marketable securities CAMBRIDGE,

Related news

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

View all latest news

Repare Therapeutics

Repare Therapeutics is an oncology company focused on precision medicine and synthetic lethality. Its story is built around targeting DNA damage-response vulnerabilities in cancer.

Recent company news

RPTXRepare Therapeutics2026-01-16 21:58 EST

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

RPTXRepare Therapeutics2025-12-24 12:00 EST

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

RPTXRepare Therapeutics2025-11-20 22:25 EST

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

RPTXRepare Therapeutics2025-11-14 21:44 EST

Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.

RPTXRepare Therapeutics2025-10-13 20:05 EST

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States